Zeynep Gokce-Samar

Zeynep Gokce-Samar

Auto-generated profile, based on publicly available information

Zeynep Gokce-Samar

Department of Pediatric Clinical Epileptology, Sleep Disorders, and Functional Neurology, Hospices Civils de Lyon, member of the ERN EpiCARE, Lyon, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
ZGZ. Gokce-Samar
Z. Gokce-Samar
JBJ. de Bellescize
J. de Bellescize
AAA. Arzimanoglou
A. Arzimanoglou
APA. Putoux
A. Putoux
NCN. Chatron
N. Chatron
VPV. Des Portes
V. Des Portes

23 January 2024 in Neurology
Verified
Journal Article
Closed access
ZGZeynep Gokce-Samar
Zeynep Gokce-Samar
AVAnnalisa Vetro
Annalisa Vetro
JBJulitta De Bellescize
Julitta De Bellescize
TPTiziana Pisano
Tiziana Pisano
LMLaloe Monteiro
Laloe Monteiro
GLGaetan Lesca
Gaetan Lesca
Heterozygous variants in RAR-related orphan receptor B (RORB) have recently been associated with susceptibility to idiopathic generalized epilepsy. However, few reports have been published so far describing pathogenic variants of this gene in patients with epilepsy and intellectual disability (ID). In this study, we aimed to delineate the epilepsy phenotype associated with RORB pathogenic variants and to provide arguments in favor of the pathogenicity of variants. Through an international collaboration, we analyzed seizure characteristics, EEG data, and genotypes of a cohort of patients with heterozygous variants in RORB. To gain insight into disease mechanisms, we performed ex vivo cortical electroporation in mouse embryos of 5 selected variants, 2 truncating and 3 missense, and evaluated on expression and quantified changes in axonal morphology. We identified 35 patients (17 male, median age 10 years, range 2.5-23 years) carrying 32 different heterozygous variants in RORB, including 28 single-nucleotide variants or small insertions/deletions (12 missense, 12 frameshift or nonsense, 2 splice-site variants, and 2 in-frame deletions), and 4 microdeletions; de novo in 18 patients and inherited in 10. Seizures were reported in 31/35 (89%) patients, with a median age at onset of 3 years (range 4 months-12 years). Absence seizures occurred in 25 patients with epilepsy (81%). Nineteen patients experienced a single seizure type: absences, myoclonic absences, or absences with eyelid myoclonia and focal seizures. Nine patients had absence seizures combined with other generalized seizure types. One patient had presented with absences associated with photosensitive occipital seizures. Three other patients had generalized tonic-clonic seizures without absences. ID of variable degree was observed in 85% of the patients. Expression studies in cultured neurons showed shorter axons for the 5 tested variants, both truncating and missense variants, supporting an impaired protein function. In most patients, the phenotype of the RORB-related disorder associates absence seizures with mild-to-moderate ID. In silico and in vitro evaluation of the variants in our cohort, including axonal morphogenetic experiments in cultured neurons, supports their pathogenicity, showing a hypomorphic effect.

8 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CNCaroline Nava
Caroline Nava
BCBenjamin Cogne
Benjamin Cogne
ASAmandine Santini
Amandine Santini
ELElsa Leitão
Elsa Leitão
FLFrançois Lecoquierre
François Lecoquierre
CDChristel Depienne
Christel Depienne
Variants in RNU4-2 , encoding the small nuclear RNA (snRNA) U4, were recently identified as a major cause of neurodevelopmental disorders (ReNU syndrome). Here, we investigated de novo variants in 50 snRNAs in a French cohort of 23,649 individuals with rare disorders and collected data of additional patients through an international collaboration. Altogether, we identified 133 probands with pathogenic or likely pathogenic variants in RNU4-2 and 15 individuals with de novo and/or recurrent variants in constrained regions of RNU5B-1 , one of five genes encoding U5. These variants cluster in evolutionarily conserved regions of U4 and U5 essential for splicing. RNU4-2 variants affecting stem III are associated with milder phenotypes than those in the T-loop (quasi-pseudoknot). Phaseable variants associated with severe phenotypes occurred on the maternal allele. Individuals with RNU4-2 variants show specific defects in alternative 5’ splice site usage, correlating with variant location and clinical severity. Additionally, we report an episignature associated with severe ReNU syndrome. This study further highlights the importance of de novo variants in snRNAs and establishes RNU5B-1 as a new neurodevelopmental disorder gene.

22 April 2025 in Epilepsia
Verified
Journal Article
Open access
ZGZeynep Gokce‐Samar
Zeynep Gokce‐Samar
GLGaetan Lesca
Gaetan Lesca
JBJulie Bourgeois‐Vionnet
Julie Bourgeois‐Vionnet
JIJean Isnard
Jean Isnard
SBSébastien Boulogne
Sébastien Boulogne
AMAlexandra Montavont
Alexandra Montavont
The most characteristic syndrome related to KCNT1 is epilepsy of infancy with migrating focal seizures. Unifocal epilepsies have also been reported, the most common being sleep‐related hypermotor epilepsy (SHE) of frontal origin. Only 10 cases of focal extrafrontal epilepsies with an insulo‐opercular or temporal origin have been reported. Among these patients suffering from focal epilepsy, only seven underwent stereoelectroencephalography (S‐EEG) describing focal or multifocal ictal onsets. We performed three S‐EEGs and one S‐EEG in two unrelated patients suffering from refractory magnetic resonance imagining‐negative SHE with insulo‐opercular seizures. None of the patients had any familial history of epilepsy or intellectual disability. They suffered from nocturnal seizures with stereotyped ictal symptoms suggestive of insulo‐opercular SHE (IO‐SHE). The four S‐EEGs revealed multifocal, bilateral, and migrating ictal activity, whereas clinical ictal semiology remained stereotyped. These S‐EEG findings led us to carry out genetic analysis, and a pathogenic missense variant of KCNT1 was found in each patient (p.Arg928Cys and p.Arg933His). Considering these two new patients, IO‐SHE represents the second most frequent type of KCNT1 ‐related focal epilepsy, and these S‐EEG findings, never described before, suggest that migrating ictal activity might be a common feature of KCNT1 ‐related epilepsy despite different syndromic presentations.

1 March 2019 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
ZGZeynep Gokce-Samar
Zeynep Gokce-Samar
KOKarine Ostrowsky-Coste
Karine Ostrowsky-Coste
DGDominique Gauthier-Morel
Dominique Gauthier-Morel
PKPascale Keo-Kosal
Pascale Keo-Kosal
JBJulitta De Regnauld De Bellescize
Julitta De Regnauld De Bellescize
AAAlexis Arzimanoglou
Alexis Arzimanoglou

28 January 2026 in Epilepsia
Verified
Journal Article
Open access
SOSebastian Ortiz
Sebastian Ortiz
LALeonardo Affronte
Leonardo Affronte
CBChiara Bagliani
Chiara Bagliani
SESerene El‐Kamand
Serene El‐Kamand
AKAnthony Sze Hon Kan
Anthony Sze Hon Kan
RMRikke S. Møller
Rikke S. Møller
Objective: Pathogenic variants in γ‐aminobutyric acid type A (GABA A ) receptor genes have been associated with a wide spectrum of neurological disorders. We aimed to delineate the clinical trajectories associated with gain‐of‐function (GoF) and loss‐of‐function (LoF) variants in GABRB2 and GABRB3 , and to develop a risk‐prediction model for gross motor dysfunction based on age at seizure onset. Methods: Clinical data, including seizure onset, epilepsy syndromes, cognitive outcomes, and gross motor function classification system (GMFCS), were collected through direct interviews, physician reports, and literature review. Kruskal–Wallis, Mantel–Cox and non‐parametric analysis of variance (ANOVA) with Dunn's corrected post hoc tests were used for statistical comparisons. A logistic ordinal regression model was developed to predict GMFCS outcomes based on age at seizure onset. Results: We analyzed a cohort of 117 individuals with pathogenic GABRB2 ( n = 49) and GABRB3 ( n = 68) variants. Fifty‐three individuals carried GoF variants and 64 carried LoF variants. The GoF group was associated with earlier seizure onset, higher seizure frequency, and lower rates of seizure freedom. Gross motor dysfunction was markedly worse in the GoF group, with 64% classified as GMFCS IV or V (non‐ambulation), compared to 7.5% in the LoF group. An inverse correlation was found between age at seizure onset and GMFCS severity in the GoF, but not the LOF group. The risk model predicted a >90% likelihood of non‐ambulation for individuals with GoF variants and seizure onset before 1 month of age, decreasing to ~35% with seizure onset after 20 months. Significance: We found a clear genotype–phenotype correlation in GABRB2‐ and GABRB3 ‐related disorders, demonstrating that GoF variants are associated with a more severe neurodevelopmental trajectory. The age at seizure onset serves as a biomarker for predicting motor outcomes in individuals with GoF variants. These findings provide guidance regarding prognosis, need for early intervention, and data for comparison of efficacy in targeted therapeutic interventions for GABA A receptor–related disorders.